Artivion, Inc. (NYSE:AORT) Stock Position Raised by Deutsche Bank AG

Deutsche Bank AG raised its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 45.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,982 shares of the company's stock after purchasing an additional 11,501 shares during the period. Deutsche Bank AG owned about 0.09% of Artivion worth $1,057,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in AORT. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after buying an additional 786 shares during the last quarter. R Squared Ltd bought a new stake in shares of Artivion in the 4th quarter worth about $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion in the 4th quarter valued at about $43,000. Venturi Wealth Management LLC bought a new position in shares of Artivion during the fourth quarter worth about $78,000. Finally, KBC Group NV grew its stake in Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company's stock worth $80,000 after purchasing an additional 1,254 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Price Performance

Shares of NYSE:AORT traded down $0.15 during trading on Friday, reaching $29.57. The company had a trading volume of 16,651 shares, compared to its average volume of 326,930. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The firm has a market capitalization of $1.26 billion, a PE ratio of -1,479.75 and a beta of 1.54. The firm's fifty day moving average is $25.52 and its 200 day moving average is $27.37.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. On average, equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Activity

In other Artivion news, Director Anthony B. Semedo sold 2,600 shares of the firm's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $28.47, for a total value of $74,022.00. Following the completion of the transaction, the director now directly owns 33,059 shares in the company, valued at $941,189.73. This trade represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jean F. Holloway sold 8,748 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total transaction of $253,692.00. Following the completion of the sale, the senior vice president now owns 178,510 shares of the company's stock, valued at approximately $5,176,790. This trade represents a 4.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,414 shares of company stock worth $1,716,731. Insiders own 7.60% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on AORT. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 target price on shares of Artivion in a research report on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, May 6th. Finally, Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.